Treatment of Ampicillin/Sulbactam-Resistant Pneumonia

General Recommendations

The Infectious Diseases Society of America recommends changing immediately to ceftriaxone 2 g IV daily plus azithromycin 500 mg IV daily, or alternatively using a respiratory fluoroquinolone (levofloxacino 750 mg IV daily or moxifloxacino 400 mg IV daily) as monotherapy for ampicillin/sulbactam-resistant pneumonia 1, 2
The preferred regimen for hospitalized patients outside of the ICU is ceftriaxone 1-2 g IV daily plus azithromycin 500 mg daily, providing coverage against typical bacterial pathogens and atypical organisms (Mycoplasma, Chlamydophila, Legionella) 1, 2
An alternative equally effective regimen is levofloxacino 750 mg IV daily or moxifloxacino 400 mg IV daily as monotherapy, with a strong recommendation and high-quality evidence 1, 2

For patients in the ICU with severe pneumonia, combination therapy with ceftriaxone 2 g IV daily (or cefotaxima 1-2 g IV every 8 hours) plus azithromycin 500 mg IV daily or a respiratory fluoroquinolone (levofloxacino 750 mg IV daily or moxifloxacino 400 mg IV daily) is obligatory 1, 2
For penicillin-allergic patients in the ICU, aztreonam 2 g IV every 8 hours plus levofloxacino 750 mg IV daily is recommended 1, 2

For patients with risk factors for Pseudomonas aeruginosa, including structural lung disease, recent hospitalization with IV antibiotics, or previous respiratory isolation of P. aeruginosa, a recommended regimen is a β-lactam antibiotic with antipseudomonal activity (piperacilina-tazobactam 4.5 g IV every 6 hours, cefepime 2 g IV every 8 hours, imipenem, or meropenem) plus ciprofloxacino 400 mg IV every 8 hours or levofloxacino 750 mg IV daily 1, 3
For patients with risk factors for MRSA, including previous MRSA infection or colonization, recent hospitalization with IV antibiotics, post-influenza pneumonia, or cavitary infiltrates on imaging, vancomicina 15 mg/kg IV every 8-12 hours (targeting a trough level of 15-20 mg/mL) or linezolid 600 mg IV every 12 hours should be added to the base regimen 1, 3, 2

The minimum duration of treatment is 5 days, and until the patient is afebrile for 48-72 hours without more than one sign of clinical instability 1, 2
The typical duration for uncomplicated community-acquired pneumonia is 5-7 days 1, 2
Extended duration (14-21 days) is recommended for specific pathogens, including Legionella pneumophila, Staphylococcus aureus, or enteric gram-negative bacilli 1, 3, 2

Patients should be switched from IV to oral therapy when they are hemodynamically stable, clinically improving, able to take oral medications, and have normal gastrointestinal function—typically by day 2-3 of hospitalization 1, 2
Oral options include amoxicilina 1 g orally three times daily plus azithromycin 500 mg orally daily, or continuing with a respiratory fluoroquinolone orally 2

Monotherapy with macrolides should not be used in hospitalized patients, as it provides inadequate coverage for typical bacterial pathogens such as S. pneumoniae 1, 2
Delaying antibiotic administration beyond 8 hours in hospitalized patients should be avoided, as it increases 30-day mortality by 20-30% 2
Indiscriminate addition of antipseudomonal or anti-MRSA coverage without documented risk factors should be avoided, as it promotes resistance without improving outcomes 2
Blood cultures and sputum culture should be obtained before initiating antibiotics in all hospitalized patients to allow for targeted therapy 1, 2